DiaSorin offers a complete TORCH line on the LIAISON® systems.
The LIAISON® Toxo IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to Toxoplasma gondii in human serum or plasma samples for screening of pregnant women. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® XL Toxo IgG Avidity assay uses chemiluminescent immunoassay (CLIA) technology for the determination of antigen-binding avidity of IgG antibodies to Toxoplasma gondii in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzer only.
The LIAISON® Toxo IgM assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of specific IgM antibodies to Toxoplasma gondii in human serum or plasma samples. The test has to be performed on the LIAISON® Analyzer.
The LIAISON® Rubella IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to rubella virus in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Rubella IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgM antibodies to rubella virus in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® CMV IgG II assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to hCMV in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® CMV IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the semi-quantitative determination of specific IgM antibodies to hCMV in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® CMV IgG Avidity II assay uses chemiluminescence immunoassay (CLIA) technology for the determination of antigen-binding avidity of IgG antibodies to hCMV in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family
The LIAISON® HSV-1/2 IgG assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to Herpes simplex virus Types 1 and/or 2 (HSV-1 and/or HSV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
LIAISON® HSV-1 Type Specific IgG assay is a chemiluminescent immunoassay (CLIA) to be used with the LIAISON® Analyzer for the qualitative determination of specific IgG antibodies to Herpes simplex virus Type 1 (HSV-1) in human serum. The test has to be performed on the LIAISON® Analyzer family.
The LIAISON® HSV-2 IgG assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to Herpes simplex virus Type 2 (HSV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® HSV-1/2 IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to Herpes simplex virus Types 1 and/or 2 (HSV-1 and/or HSV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Biotrin Parvovirus B19 IgG assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to parvovirus B19 in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Biotrin Parvovirus B19 IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to parvovirus B19 in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The use of some assays has become particularly important after implementation of screening programs in a number of countries to identify pregnant women at risk of materno-fetal infections caused by, Toxoplasma, Parvovirus B19, Rubella, hCMV and Herpes simplex viruses (the so-called TORCH panel) and to monitor the outcome once one disease is recognized.
Infection with TORCH organisms frequently causes only mild maternal infection, but can result in serious consequences for the fetus. For this reason, the performance of serological tests is extremely important for accurate diagnosis and correct clinical management of patients. To improve serological diagnosis, measurement of IgG avidity has recently been introduced to stage the infection and calculate the risk to the fetus. The ability to distinguish between ongoing and past infection helps to avoid anxiety and unnecessary treatment in the pregnant woman.
